Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
02 2024
Historique:
received: 30 10 2023
accepted: 22 01 2024
medline: 18 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: ppublish

Résumé

The 2017 EULAR/ACR classification criteria for adult/juvenile idiopathic inflammatory myopathies (IIM) were established using a data-driven approach by an international group of myositis experts to allow classification of IIM and its major subtypes. Since their publication, the performance of the criteria has been tested in multiple cohorts worldwide and significant limitations have been identified. Moreover, the understanding and classification of IIM have evolved since 2017. This scoping review was undertaken as part of a large international project to revise the EULAR/ACR criteria and aims to i) summarise the evidence from the current literature on the performance characteristics of the 2017 EULAR/ACR classification criteria in various cohorts and IIM subtypes, and ii) delineate the factors that need to be considered in the revision of the classification criteria. A systematic search of Medline (via PubMed), Cumulative Index to Nursing and Allied Health Literature, and conference abstract archives was conducted independently by three investigators for studies on the EULAR/ACR criteria published between October 2017 and January 2023. This scoping review of 19 articles and 13 abstracts revealed overall good performance characteristics of the EULAR/ACR criteria for IIM, yet deficiencies in lack of inclusion of certain IIM subtypes, such as immune mediated necrotising myopathy, amyopathic dermatomyositis, antisynthetase syndrome and overlap myositis. Published modifications that may improve the performance characteristics of the criteria for classification of IIM subtypes were also summarised. The results of this review suggest that a revision of the EULAR/ACR criteria is warranted.

Identifiants

pubmed: 38436279
pii: 20507
doi: 10.55563/clinexprheumatol/vuc5py
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-412

Auteurs

Didem Saygin (D)

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, PA, USA.

Stefanie Glaubitz (S)

Department of Neurology, University Medical Center Göttingen, Germany.

Rachel Zeng (R)

Department of Neurology, University Medical Center Göttingen, Germany.

Matteo Bottai (M)

Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Marianne de Visser (M)

Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.

Mazen M Dimachkie (MM)

Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.

David Fiorentino (D)

Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.

Ingrid Gerhardson (I)

Patient Research partner, Stockholm, Sweden.

Masataka Kuwana (M)

Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Frederick W Miller (FW)

Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.

Merrilee Needham (M)

Department of Neurology, Fiona Stanley Hospital, IIID Murdoch University and University of Notre Dame, Perth, Australia.

Lisa G Rider (LG)

Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA.

Yasser Salem (Y)

Physical Therapy Program, Hofstra University, Hemstead, NY, USA.

Silke Schlüter (S)

Diagnosegruppe Myositis, Deutsche Gesellschaft für Muskelkranke, Freiburg, Germany.

Samuel K Shinjo (SK)

Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.

Guochun Wang (G)

Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, China.

Victoria P Werth (VP)

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.

Rohit Aggarwal (R)

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, PA, USA. aggarwalr@upmc.edu.

Ingrid E Lundberg (IE)

Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm; and Department of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH